Diabetes News and Research

Latest Diabetes News and Research

Experts address fundamental questions related to renal failure in ICU

Despite the fact that recent medical advances have allowed healthcare professionals to stabilize patients who would have otherwise died, many stabilized patients later develop organ system failure. In fact, acute renal failure is one of the biggest threats to critically ill patients: forty percent of patients with this condition die.

14 May 2010

BioTrends reports increase in usage of Actemra for RA

BioTrends is pleased to announce the publication of the second wave of a syndicated report, LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first IL-6 receptor inhibitor agent approved for rheumatoid arthritis (RA). This report is the second in a three-wave series derived from on-line survey responses from 80 rheumatologists and qualitative interviews with 20 rheumatologists.

14 May 2010

Off-label use of AAs among elderly associated with increased risk of diabetes: Study

A new study yields important new evidence that the use of atypical antipsychotics among the elderly for off-label purposes is associated with increased risk of developing diabetes.

14 May 2010

New cases of Type 1 diabetes in young children to double by 2020: The Lancet

By 2020, new cases of Type 1 diabetes in children younger than five are expected to double if current trends continue, according to a study published in The Lancet. Diabetes is an epidemic, with numbers of those suffering from diabetes and its complications increasing worldwide.

14 May 2010

GRNCM1 do not cause cardiac arrhythmias after transplantation: Preclinical study

Geron Corporation today reported positive preclinical study data showing that GRNCM1, Geron's cardiomyocyte product derived from human embryonic stem cells, does not cause cardiac arrhythmias after transplantation into a model of chronic heart damage designed to test this potential safety concern.

14 May 2010

Jennerex to present key data on JX-594 Phase 1 dose escalation clinical study at ASGCT Annual Meeting

Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced that key data from its JX-594 intravenous administration Phase 1 dose escalation clinical study will be presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting taking place May 19-22, 2010, in Washington DC.

14 May 2010

Minnesota lawmakers debate budget, Medicaid expansion

More budget talks were expected Thursday as Minnesota's legislative session hurtled toward a midnight Sunday deadline with no deal on a $3 billion deficit. The Democratic-controlled Legislature defied another veto threat from Republican Gov. Tim Pawlenty late Wednesday and sent him a health and welfare package he opposes.

14 May 2010

New Infrared Relief therapy now available for patients with diabetic neuropathies

Genesis Spine Associates now offers Infrared Relief - a new, highly effective pain management therapy using infrared light for patients suffering from diabetic neuropathies. This new therapy offers a simple, painless option for managing patients' pain without potentially dangerous drugs or surgery.

14 May 2010

Groups plead for more health funding as Chairman warns about cuts to proposed HHS budget

House Appropriations Committee Chairman David Obey, D-Wis., said Wednesday that groups pressing for $14 billion more in funding for education, health and labor programs will likely be disappointed because the budget proposed by President Barack Obama already faces cuts of about $3.5 billion in those areas.

14 May 2010

Derma Sciences first-quarter net sales up 23% to $12,844,382

Derma Sciences, Inc., a specialty medical device/pharmaceutical company focused on advanced wound care, reported financial and operating results today for the three months ended March 31, 2010.

14 May 2010

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

Repligen Corporation announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor. This is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 subjects.

13 May 2010

Medco announces new $3 billion share repurchase program

Medco Health Solutions, Inc. today announced that its Board of Directors has unanimously approved a new $3 billion share repurchase program.

13 May 2010

Data on Qnexa to be presented at World Congress on CODHy in Prague

VIVUS, Inc. today announced that data on Qnexa, an investigational drug candidate, will be presented at the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension in Prague, Czech Republic.

13 May 2010

Researchers provide better understanding of anti-cell death proteins and potential antagonist to defeat them

Cancer uses devious means to evade treatment and survive. One prime example is the way tumors express anti-cell death (anti-apoptotic) proteins to resist chemotherapy and radiation. However, the Pellecchia laboratory at Sanford-Burnham Medical Research Institute has made two recent discoveries that may help curb these anti-apoptotic proteins and make current treatments more effective.

13 May 2010

PAREXEL further expands presence in China with offices in Chengdu and Guangzhou

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that the Company has opened offices in Chengdu and Guangzhou, China to support a growing requirement for a broad range of clinical development and regulatory consulting capabilities in the country and throughout the Asia/Pacific region.

From Parexel 13 May 2010

SAGE launches further two Therapeutic Advances journals

SAGE has extended its suite of Therapeutic Advances journals with the launch of a further two titles: Therapeutic Advances in Chronic Disease and Therapeutic Advances in Endocrinology and Metabolism.

13 May 2010

Increased IR associated with HCC development in chronic HCV-infected patients

Recent studies have demonstrated that type 2 diabetes mellitus (DM) is associated with high risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C. Insulin resistance (IR), which correlates inversely with circulating adiponectin concentration, is a consistent finding in patients with type 2 DM.

13 May 2010

Researchers to discuss various implications for personalized medicine during one-day symposium

On May 27, researchers with the National Human Genome Research Institute and the National Cancer Institute, along with Group Health Cooperative in Seattle and Henry Ford Health System, will debate and discuss that question during the one-day symposium "Multiplex Initiative: Implications for Personalized Medicine."

13 May 2010

Rapid responders in novel behavior treatment for IBS maintain improvement at 3-month follow-up

Nearly one-third of patients with irritable bowel syndrome (IBS) who underwent a novel behavior treatment developed by a University at Buffalo behavioral scientist achieved significant relief within four weeks of beginning treatment.

13 May 2010

RYGB surgery increases insulin activity in diabetes mellitus patients

Diabetes mellitus is a chronic metabolic disease resulted from, either decreased production of insulin or increased resistance to it from peripheral tissues or both factors combined together. While medical treatment remains the mainstay of treatment for diabetes, some surgical procedures, such as Roux-en-Y gastric bypass, have demonstrated some potential to be a treatment option for diabetes.

13 May 2010

Diabetes News and Research

Latest Diabetes News and Research

Experts address fundamental questions related to renal failure in ICU

BioTrends reports increase in usage of Actemra for RA

Off-label use of AAs among elderly associated with increased risk of diabetes: Study

New cases of Type 1 diabetes in young children to double by 2020: The Lancet

GRNCM1 do not cause cardiac arrhythmias after transplantation: Preclinical study

Jennerex to present key data on JX-594 Phase 1 dose escalation clinical study at ASGCT Annual Meeting

Minnesota lawmakers debate budget, Medicaid expansion

New Infrared Relief therapy now available for patients with diabetic neuropathies

Groups plead for more health funding as Chairman warns about cuts to proposed HHS budget

Derma Sciences first-quarter net sales up 23% to $12,844,382

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

Medco announces new $3 billion share repurchase program

Data on Qnexa to be presented at World Congress on CODHy in Prague

Researchers provide better understanding of anti-cell death proteins and potential antagonist to defeat them

PAREXEL further expands presence in China with offices in Chengdu and Guangzhou

SAGE launches further two Therapeutic Advances journals

Increased IR associated with HCC development in chronic HCV-infected patients

Researchers to discuss various implications for personalized medicine during one-day symposium

Rapid responders in novel behavior treatment for IBS maintain improvement at 3-month follow-up

RYGB surgery increases insulin activity in diabetes mellitus patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Diabetes News and Research

Latest Diabetes News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in